Frontiers in Anti-Cancer Drug Discovery

Volume 7


Atta-ur-Rahman, FRS , M. Iqbal Choudhary

DOI: 10.2174/97816810825161160701
eISBN: 978-1-68108-251-6, 2016
ISBN: 978-1-68108-252-3
ISSN: 2451-8395 (Print)
ISSN: 1879-6656 (Online)

Indexed in: EMBASE, EBSCO, Ulrich's Periodicals Directory.

"Frontiers in Anti-Cancer Drug Discovery" is an eBook series devoted to publish...[view complete introduction]
US $
Buy Personal eBook
Order Library eBook
Order Printed Copy
Order PDF + Printed Copy (Special Offer)

*(Excluding Mailing and Handling)

🔒Secure Checkout Personal information is secured with SSL technology
Download Flyer

Malignant Pleural Mesothelioma (MPM): Latent Disease

- Pp. 3-92 (90)

M. Genovés Crespo, F.J. Callejas González, R.D. García Ángel, W. Mayoris Almonte and F.J. Agustín Martínez


Malignant pleural mesothelioma (MPM) is a cancer with aggressive nature and poor prognosis (the median survival ranges from 9-18 months). The worldwide incidence of this disease is increasing, with 2180 estimated new cases diagnosed in the United States in 2013. Despite the apparent benefits offered by the multimodal approach (a combination of surgery, chemotherapy -cisplatin/ pemetrexed- and radiotherapy), survival remains poor. As a consequence, multiple therapies aiming to improve the evolution of the disease are under investigation. In this chapter, we will summarize some of the new preclinical and early clinical developments in the treatment of MPM, which include mesothelin specific antibody and toxin therapies, gene therapy, interleukin-4 (IL-4) receptor toxins and dendritic cell vaccines, among others.

Purchase Chapter  Book Details


Webmaster Contact: Copyright © 2019 Bentham Science